Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement
Methodological detailsGRADE
- GRADE
Recommendations
As issued by the authors
- weak recommendation, very low-quality evidence
In patients with osteoporosis on antiresorptive therapy, the Taskforce suggests that antiresorptive therapy does not need to be stopped prior to proceeding with dental implant
- moderate certainty
Long-term bisphosphonate use maybe associated with a small increase in the risk of medication-related osteonecrosis of the jaw (MRONJ) (3 cases per 1000 patients; aHR 4.09, 95% CI 2.75-6.09, P < .001)
Original publication
Antiresorptive Therapy to Reduce Fracture Risk and Effects on Dental Implant Outcomes in Patients With Osteoporosis: A Systematic Review and Osteonecrosis of the Jaw Taskforce Consensus Statement. Endocr Pract. Published May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →